Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma

Conditions: Safety Issues; Efficacy; MTD Interventions: Drug: Sintilimab 200mg+MB07133 600mg Sponsors: Xi ' an Xintong Pharmaceutical Research Co.,Ltd.; The First Hospital of Jilin University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials